Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chadi Nouneh

Cardiovascular Disease Evergreen Park, IL Medical Doctor

NPI 1922100403 CMS profile 223530

3545 W 95Th St, Evergreen Park, IL 60805

Open in the dashboard

General payments

$28,343

659 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chadi Nouneh of Evergreen Park, IL is reported in the CMS Open Payments database as having received $28,343 across 659 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,865 93
2024 General $1,477 86
2023 General $1,593 87
2022 General $1,503 84
2021 General $11,292 124
2020 General $440 33
2019 General $10,172 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chadi Nouneh
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Chadi Nouneh were reported at $1,865. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Chadi Nouneh Cardiovascular Disease median Middle half National median
2019 $10,172 $450 $127–$1,392 $163
2020 $440 $242 $77–$751 $114
2021 $11,292 $335 $101–$1,037 $132
2022 $1,503 $395 $121–$1,211 $149
2023 $1,593 $443 $136–$1,283 $160
2024 $1,477 $450 $136–$1,323 $164
2025 $1,865 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $14,157 47 payments
  2. Philips Electronics North America Corporation $2,072 6 payments
  3. Janssen Pharmaceuticals, Inc $1,195 100 payments
  4. Cardiva Medical, Inc. $1,156 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,106 71 payments
  6. AstraZeneca Pharmaceuticals LP $991 59 payments
  7. Terumo Medical Corporation $988 10 payments
  8. Novartis Pharmaceuticals Corporation $945 56 payments
  9. Pfizer Inc. $880 47 payments
  10. Medtronic, Inc. $828 47 payments
  11. Other $4,026 208 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,022 638 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,000 4 payments
  3. Travel and Lodging $3,258 8 payments
  4. Honoraria $1,000 1 payment
  5. Education $63 8 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Pain Management $6,356 16 payments
  2. WATCHMAN Structural Heart $4,534 21 payments
  3. WATCHMAN Structural Heart $3,098 3 payments
  4. IGT D Peripheral $2,000 3 payments
  5. XARELTO $1,195 100 payments
  6. Vascular Closure Device $1,022 2 payments
  7. Navicross $868 5 payments
  8. ENTRESTO $707 45 payments
  9. ELIQUIS $706 38 payments
  10. Glidesheath $592 4 payments
  11. Other $10,292 512 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

6,023

Median for Cardiology: 2,533

Drug cost

$1,014,587

Median for Cardiology: $485,213

Branded share of claims

24.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 394 $406,383
Entresto Sacubitril/Valsartan Brand 221 $237,073
Jardiance Empagliflozin Brand 103 $107,810
Xarelto Rivaroxaban Brand 75 $84,184
Repatha Sureclick Evolocumab Brand 51 $39,040
Farxiga Dapagliflozin Propanediol Brand 43 $36,803
Brilinta Ticagrelor Brand 41 $34,094
Metoprolol Succinate Generic 769 $10,824
Atorvastatin Calcium Generic 517 $6,353
Losartan Potassium Generic 477 $4,729

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$805,200

Of which drugs: $128

Medicare patients

1,458

Average age 76

Services billed

10,105

850 women, 608 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 46%
Diabetes 44%
Chronic kidney disease 42%
Heart failure 37%
Atrial fibrillation 32%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, protamine sulfate, per 10 mg J2720 Office 18 69 $80
Injection, fentanyl citrate, 0.1 mg J3010 Office 29 34 $23
Injection, midazolam hydrochloride, per 1 mg J2250 Office 29 38 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$279 103 —
CAMZYOS
$137 — —
ELIQUIS
$128 394 —
WAINUA
$107 — —
INJECTAFER
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

659 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record